Research Topics
| Talia FosterSummaryPublications
| Collaborators
|
Detail Information
Publications
Economic burden of follicular non-Hodgkin's lymphomaTalia Foster
Abt Bio Pharma Solutions, Inc, Lexington, Massachusetts, USA
Pharmacoeconomics 27:657-79. 2009..As new treatments for FNHL come to market, more real-life cost data are imperative to calculate their relative cost effectiveness...
Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspectiveNandini Hadker
Abt Bio Pharma Solutions, Inc, Lexington, MA 02420, USA
J Med Econ 13:728-37. 2010..Early diagnosis may be possible with a new serum test, with resulting clinical and economic benefits versus standard practice. The authors evaluated the financial impact to the UK National Health Service (NHS)...
Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) dataJeffrey D Miller
Boston Health Economics, Inc, 20 Fox Road, Waltham, Massachusetts 02451, USA
COPD 2:311-8. 2005..Results of our study indicate that COPD-associated healthcare utilization and expenditures are considerable, and that annual per-patient costs of COPD are comparable to those of other chronic diseases of the middle-aged and elderly...
Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic reviewLindsay Hallett
United BioSource Corporation, Lexington, MA, USA
Curr Med Res Opin 27:1571-83. 2011..Tuberous sclerosis complex (TSC) is a progressive genetic disorder characterized by pervasive benign tumor growth. We sought to assess the current understanding of burden of TSC-related neurological manifestations...
